“Women experience this complication most often in their third trimester due to bodily changes that make them more likely to develop blood clots as a protective mechanism against excessive bleeding ...

More than 8 million people in the U.S. take blood thinners to prevent dangerous clots. At the same time, the drugs are ...

If approved, marstacimab would be the first non-factor prophylactic treatment indicated for pediatric patients aged 6 to 11 years with hemophilia B.

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...

An ovarian cyst rupture can cause sudden pain, bleeding, and other symptoms. Learn the signs, treatments, and what to expect after an ovarian cyst ruptures.

Clinical trial results indicate a protein, rFVIIa, may benefit certain stroke patients when administered quickly, with a focus on acute intracerebral hemorrhage treatments.

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

Nursing-led remote evaluation improved triage, risk identification, and multidisciplinary preparedness in adolescents with ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Common causes of postmenopausal bleeding include atrophy and fibroids. Learn about risk factors, treatments, and when to ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...